Signal intensity of normal breast tissue at MR mammography on midfield: Applying a random coefficient model evaluating the effect of doubling the contrast dose

European Journal of Radiology

Volumn 69, Issue 1, 2009, Pages 93-101

  Marklund, Mette ^a   Christensen, Robin ^a   Torp Pedersen, Søren ^a   Thomsen, Carsten ^b   Nolsøe, Christian P ^c  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KØGE HOSPITAL   (Denmark)

Author keywords

Contrast media; Dynamic; Healthy volunteers; Mammography; MRI

Indexed keywords

BREAST TISSUES; ENHANCEMENT RATIOS; HEALTHY VOLUNTEERS; HIGH DOSES; INJECTION RATES; MR MAMMOGRAPHIES; MRI; POST-PROCESSING; RANDOM COEFFICIENTS; REGION OF INTERESTS; SIGNAL INTENSITIES;

DIAGNOSTIC RADIOGRAPHY; GADOLINIUM; LOUDSPEAKERS; MEDICAL IMAGING;

CONTRAST MEDIA;

GADODIAMIDE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HUMAN; HUMAN EXPERIMENT; MAGNETIC RESONANCE MAMMOGRAPHY; MAMMOGRAPHY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL;

ADULT; BREAST; COMPUTER SIMULATION; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 58149527085     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2007.09.006     Document Type: Article

References (31)

1. Van G.M., Tjalma W., Schelfout K., Verslegers I., Biltjes I., and Parizel P. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol 32 9 (2006) 901-910
2. Wang S-C. Magnetic resonance mammography. www.emedicine.com/radio/topic792.htm; 2004. Ref type: Internet communication.
3. Macura K.J., Ouwerkerk R., Jacobs M.A., and Bluemke D.A. Patterns of enhancement on breast MR images: interpretation and imaging pitfalls. Radiographics 26 6 (2006) 1719-1734
4. Heywang-Köbrunner S.H., Haustein J., Pohl C., et al. Contrast-enhanced MR imaging of the breast: comparison of two different doses of gadopentetate dimeglumine. Radiology 191 3 (1994) 639-646
5. Gebker R., Paetsch I., Neuss M., et al. Determinants of myocardial response in CMR perfusion imaging using Gd-BOPTA (Multihance). J Cardiovasc Magn Reson 7 3 (2005) 565-572
6. Knauth M., Forsting M., Hartmann M., Heiland S., Balzer T., and Sartor K. MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. Am J Neuroradiol 17 10 (1996) 1853-1859
7. Runge V.M., Wells J.W., and Williams N.M. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection. Invest Radiol 31 8 (1996) 472-478
8. Runge V.M. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model. Invest Radiol 33 5 (1998) 263-267
9. van Waesberghe J.H., Castelijns J.A., Roser W., et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. Am J Neuroradiol 18 7 (1997) 1279-1285
10. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 9263 (2001) 1191-1194
11. Laird N.M., and Ware J.H. Random-effects models for longitudinal data. Biometrics 38 4 (1982) 963-974
12. Sullivan L.M., Dukes K.A., and Losina E. Tutorial in biostatistics. An introduction to hierarchical linear modelling. Stat Med 18 7 (1999) 855-888
13. Morrell C.H. Likelihood ratio testing of variance components in the linear mixed-effects model using restricted maximum likelihood. Biometrics 54 4 (1998) 1560-1568
14. Littell R.C., Henry P.R., and Ammerman C.B. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci 76 4 (1998) 1216-1231
15. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D., and Schabenberger O. SAS for mixed models. 2nd ed. (2006), SAS Institute Inc., Cary, NC
16. Singer J.D. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat (2007)
17. Patterson H.D., and Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrica 58 3 (1971) 545-554
18. Marklund M., Moller J.M., Burchard A.J., et al. Is 0.6 T magnetic resonance mammography adequate in the detection of breast cancer?. Acta Radiol 47 5 (2006) 446-453
19. Marklund M., Torp-Pedersen S., Bentzon N., Thomsen C., Roslind A., and Nolsoe C.P. Contrast kinetics of the malignant breast tumour-Border versus centre enhancement on dynamic midfield MRI. Eur J Radiol (2007)
20. Rusinek H., Lee V.S., and Johnson G. Optimal dose of Gd-DTPA in dynamic MR studies. Magn Reson Med 46 2 (2001) 312-316
21. Vogel P.M., Georgiade N.G., Fetter B.F., Vogel F.S., and McCarty Jr. K.S. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 104 1 (1981) 23-34
22. Delille J.P., Slanetz P.J., Yeh E.D., Kopans D.B., and Garrido L. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 11 4 (2005) 236-241
23. Kuhl C.K., Bieling H.B., Gieseke J., et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203 1 (1997) 137-144
24. Muller-Schimpfle M., Ohmenhauser K., Stoll P., Dietz K., and Claussen C.D. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203 1 (1997) 145-149
25. Rieber A., Nussle K., Merkle E., Kreienberg R., Tomczak R., and Brambs H.J. MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease. Eur Radiol 9 6 (1999) 1107-1112
26. Hulka C.A., Smith B.L., Sgroi D.C., et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 197 1 (1995) 33-38
27. Delille J.P., Slanetz P.J., Yeh E.D., Kopans D.B., Halpern E.F., and Garrido L. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging-initial observations. Radiology 235 1 (2005) 36-41
28. Harpur E.S., Worah D., Hals P.A., Holtz E., Furuhama K., and Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28 Suppl 1 (1993) S28-S43
29. New Zealand Medicines and Medical Devices Safety Authority. Omniscan (Gadodiamide), Product Information; 2007. Ref type: Internet communication.
30. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 1 (2007) 148-157
31. Knopp M.V., Bourne M.W., Sardanelli F., et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. Am J Roentgenol 181 3 (2003) 663-676